Clinical Trials Logo

Clinical Trial Summary

Sarcoidosis is a heterogeneous disorder of unknown etiology whose signature lesions are granulomatous inflammatory infiltrates in involved tissues. Tissue commonly affected are lungs, skin, eyes, lymph nodes and the heart. In this latter case, cardiac sarcoidosis (CS) can lead to atrioventricular (AV) blocks, ventricular arrhythmias, heart failure (HF) and sudden cardiac death. Similar to other involved organs, cardiac disease generally progresses from areas of focal inflammation to scar. However, the natural history of CS is not well characterized complicating an immediate and definitive diagnosis. The management of CS often requires multidisciplinary care teams and is challenged by data limited to small observational studies and from the high likelihood of side effects of most of the treatments currently used (eg: corticosteroids, methotrexate and TNF-alfa inhibitors). Interleukin-1 (IL-1) is the prototypical pro-inflammatory cytokine, also referred to as master regulator of the inflammatory response, involved in virtually every acute process. There is evidence that IL-1 plays a role in mouse model of sarcoidosis and human pulmonary lesions as the presence of the inflammasome in granulomas of the heart of patients with cardiac sarcoidosis, providing additional support for a role of IL-1 in the pathogenesis of CS. However, IL-1 blockade has never been evaluated as a potential therapeutic agent for cardiac sarcoidosis. In the current study, researchers aim to evaluate the safety and efficacy of IL-1 blockade with anakinra (IL-1 receptor antagonist) in patients with cardiac sarcoidosis.


Clinical Trial Description

Researchers will perform an open label randomized clinical trial of anakinra (recombinant IL-1 receptor antagonist, Kineret, SOBI, Sweden) given for 4 weeks in 28 patients with cardiac sarcoidosis (defined using Heart Rhythm Society diagnostic criteria). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04017936
Study type Interventional
Source Virginia Commonwealth University
Contact Jordana Kron, MD
Phone 804-828-7565
Email jordana.kron@vcuhealth.org
Status Recruiting
Phase Phase 2
Start date October 23, 2020
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT03705884 - PET/MR Imaging In Patients With Cardiac Sarcoidosis N/A
Recruiting NCT06131112 - Macrophage PET/CT Imaging Using 64Cu-DOTATATE for the Diagnosis of Cardiac Sarcoidosis
Terminated NCT03923049 - Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis N/A
Not yet recruiting NCT05954507 - Evaluation of the Prognostic Value of PET/MRI in Cardiac Sarcoidosis N/A
Recruiting NCT04737317 - Diagnostic Criteria in Cardiac Sarcoidosis
Recruiting NCT06409585 - Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Recruiting NCT03057002 - UTSW HP [13-C] Pyruvate Injection in HCM
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Withdrawn NCT02812849 - Somatostatin Receptor Imaging in Cardiac Sarcoidosis
Completed NCT01729169 - Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET N/A
Completed NCT03549598 - d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Phase 4
Recruiting NCT04758650 - Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis Phase 2
Recruiting NCT04206163 - Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis N/A
Recruiting NCT05499637 - [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation Phase 2
Recruiting NCT03593759 - Cardiac Sarcoidosis Randomized Trial Phase 3
Recruiting NCT05145023 - Development and Validation of a Health-related Quality of Life Tool for Patients With Cardiac Sarcoidosis
Enrolling by invitation NCT04774549 - Inflammatory Cardiomyopathy Bern Registry
Recruiting NCT03049254 - Mayo AVC Registry and Biobank
Completed NCT03746847 - PET Imaging in Patients With Suspected Cardiac Sarcoidosis
Recruiting NCT01477359 - Cardiac Sarcoidosis Multi-Center Prospective Cohort